Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Tivenix SA is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, PRIEST, AARON A, who is the busiest examiner with 1 pending action. The matter is situated in 1 distinct art unit, indicating a focused administrative presence.
The company's current workload consists of 1 pending office action, which is being reviewed by 1 distinct examiner. This represents a focused prosecution effort with a single point of contact at the patent office for the pending intellectual property. PRIEST, AARON A is the sole examiner involved, meaning his specific preferences will guide the outcome of the 1 pending office action.
Because the activity is concentrated in 1 distinct art unit, the company only needs to navigate the procedural standards of one specialized division. However, this lack of diversification means the entire active portfolio is subject to the review of a single individual. Practitioners should focus on the specific history of PRIEST, AARON A to efficiently resolve the 1 pending office action in the Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PRIEST, AARON A | 1 | 61.4% | +25.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18697252 | A METHOD FOR DIAGNOSING AND PREDICTING PROGRESSION OF NEURODEGENERATIVE DISEASES OR DISORDERS | PRIEST, AARON A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18697252 | A METHOD FOR DIAGNOSING AND PREDICTING PROGRESSION OF NEURODEGENERATIVE DISEASES OR DISORDERS | PRIEST, AARON A | — |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18697252 | A METHOD FOR DIAGNOSING AND PREDICTING PROGRESSION OF NEURODEGENERATIVE DISEASES OR DISORDERS | PRIEST, AARON A | 1681 | §101§102§103§112 | Non-Final OA | — | Pending | Mar 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTivenix SA has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Aaron A Priest has the most, with 1 of Tivenix SA's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
